Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of the effectiveness of L-carnitine and curcumin in the treatment of non-alcoholic fatty liver
IRCT20210412050944N2Phase 2Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of levocarnitine and curcumin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Qazvin University of Medical Sciences. Started Sep 2022; status: completed.
02
Drugs
levocarnitinecurcumin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20210412050944N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210412050944N2.